News Quantified

KALV – kalvista pharmaceuticals, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

KalVista Pharmaceuticals to Report Eight Months Fiscal Year 2025 Financial Results and Provide Corporate Update on March 25, 2026

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KalVista Pharmaceuticals Presents New Data Highlighting High Patient Satisfaction and Evolving Treatment Trends with EKTERLY® (sebetralstat) [Yahoo! Finance]

KalVista Pharmaceuticals Presents New Data Highlighting High Patient Satisfaction and Evolving Treatment Trends with EKTERLY® (sebetralstat)

KalVista Pharmaceuticals to Present at Upcoming Investor Conferences

5.3%

BEAT

-9.4%

MISS

Form 4 KalVista Pharmaceuticals For: Mar 06 Filed by: Palleiko Benjamin L

Form 4 KalVista Pharmaceuticals For: Feb 21 Filed by: Audhya Paul K.

Form 4 KalVista Pharmaceuticals For: Feb 21 Filed by: Palleiko Benjamin L

Form 4 KalVista Pharmaceuticals For: Feb 21 Filed by: Yea Christopher

Form 4 KalVista Pharmaceuticals For: Feb 21 Filed by: Sweeny Nicole

Top News Gainers

9/9 Q1/2019 7/31/2019 EPS -0.420 ZacksConsensus -0.610 ActVsEst 0.190 - Beat 9.9%

3/23 Form SC 13G KalVista Pharmaceuticals Filed by: Ikarian Capital, LLC 8.8%

4/9 KalVista Pharmaceuticals to Present at 19th Annual Needham Healthcare Conference 8.4%

12/7 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $16.00 price target on the stock. 6.6%

11/29 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. 5.0%

7/19 Form 4 KalVista Pharmaceuticals For: Jul 17 Filed by: Cha Albert 4.4%

9/30 Form 4 KalVista Pharmaceuticals For: Sep 26 Filed by: SOLAND DANIEL B 4.3%

6/16 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. 4.2%

5/14 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. 3.4%

10/25 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $35.00 price target on the stock. 3.2%

Top News Decliners

3/10 Form 10-Q KalVista Pharmaceuticals For: Jan 31 -14.8%

3/10 KalVista Pharmaceuticals Reports Fiscal Third Quarter Results -13.7%

4/30 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -7.7%

5/31 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) had its "buy" rating re-affirmed by analysts at Roth Capital. -7.7%

12/26 Form 4 KalVista Pharmaceuticals For: Dec 20 Filed by: Crockett Thomas Andrew -6.8%

12/3 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $35.00 price target on the stock. -6.8%

2/22 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -4.8%

7/1 Form 8-K KalVista Pharmaceuticals For: Jun 26 -4.5%

9/4 KalVista Pharmaceuticals: Our Verdict [Seeking Alpha] -4.3%

5/15 Kalvista Pharmaceuticals Inc (NASDAQ: KALV) had its price target raised by analysts at Roth Capital from $25.00 to $30.00. They now have a "buy" rating on the stock. -4.2%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day